Thursday, 28 July 2011

Metamizol Stada




Metamizol Stada may be available in the countries listed below.


Ingredient matches for Metamizol Stada



Metamizole

Metamizole magnesium (a derivative of Metamizole) is reported as an ingredient of Metamizol Stada in the following countries:


  • Spain

International Drug Name Search

Sunday, 24 July 2011

Lignopanthen




Lignopanthen may be available in the countries listed below.


Ingredient matches for Lignopanthen



Dexpanthenol

Dexpanthenol is reported as an ingredient of Lignopanthen in the following countries:


  • Oman

Lidocaine

Lidocaine hydrochloride (a derivative of Lidocaine) is reported as an ingredient of Lignopanthen in the following countries:


  • Oman

International Drug Name Search

Saturday, 23 July 2011

Safyral


Safyral is a brand name of drospirenone/ethinyl estradiol/levomefolate calcium, approved by the FDA in the following formulation(s):


SAFYRAL (drospirenone; ethinyl estradiol; levomefolate calcium - tablet; oral)



  • Manufacturer: BAYER HLTHCARE

    Approval date: December 16, 2010

    Strength(s): 3MG,N/A;0.03MG,N/A;0.451MG,0.451MG

Has a generic version of Safyral been approved?


No. There is currently no therapeutically equivalent version of Safyral available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Safyral. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Solid dosage forms that contain clathrates of 17.alpha.-ethinyl estradiol
    Patent 5,798,338
    Issued: August 25, 1998
    Inventor(s): Backensfeld; Thomas & Tack; Johannes
    Assignee(s): Schering Aktiengesellschaft
    A method and pharmaceutical compositions are disclosed for reducing oxidative degradation of 17 .alpha.-ethinylestradiol comprising combining the estradiol with an effective amount of cyclodextrin, thus forming a cyclodextrin clathrate of the steroid.
    Patent expiration dates:

    • July 10, 2015
      ✓ 
      Drug product




  • Stable crystalline salts of 5-methyltetrahydrofolic acid
    Patent 6,441,168
    Issued: August 27, 2002
    Inventor(s): Rudolf; Müller & Rudolf; Moser & Thomas; Egger
    Assignee(s): Eprova AG
    This invention relates to stable crystalline salts of 5-methyl-(6R,S)-, -(6S)- and -(6R)-tetrahydrofolic acid, to methods of producing these salts and to the use thereof use as a constituent for the production of drugs or as a food additive, and to preparations containing these salts.
    Patent expiration dates:

    • April 17, 2020
      ✓ 
      Drug substance




  • Cyclodextrin-drospirenone inclusion complexes
    Patent 6,958,326
    Issued: October 25, 2005
    Inventor(s): Backensfeld; Thomas & Heil; Wolfgang & Lipp; Ralph
    Assignee(s): Schering AG
    Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
    Patent expiration dates:

    • December 20, 2021
      ✓ 
      Drug product




  • Compositions of estrogen-cyclodextrin complexes
    Patent 7,163,931
    Issued: January 16, 2007
    Inventor(s): Backensfeld; Thomas & Heil; Wolfgang & Lipp; Ralph
    Assignee(s): Schering Aktiengesellchaft
    Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
    Patent expiration dates:

    • March 3, 2022
      ✓ 
      Patent use: PREVENTION OF PREGNANCY



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 16, 2013 - NEW PRODUCT

See also...

  • Safyral Consumer Information (Drugs.com)
  • Safyral Consumer Information (Wolters Kluwer)
  • Safyral Consumer Information (Cerner Multum)
  • Safyral Advanced Consumer Information (Micromedex)
  • Drospirenone/Ethinyl Estradiol/Levomefolate Consumer Information (Wolters Kluwer)
  • Drospirenone, ethinyl estradiol, and levomefolate Consumer Information (Cerner Multum)
  • Drospirenone, ethinyl estradiol, and levomefolate Advanced Consumer Information (Micromedex)

Thursday, 21 July 2011

Lumbax




Lumbax may be available in the countries listed below.


Ingredient matches for Lumbax



Ibuprofen

Ibuprofen is reported as an ingredient of Lumbax in the following countries:


  • Venezuela

International Drug Name Search

Novo-Tamsulosin




Novo-Tamsulosin may be available in the countries listed below.


Ingredient matches for Novo-Tamsulosin



Tamsulosin

Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Novo-Tamsulosin in the following countries:


  • Canada

International Drug Name Search

Wednesday, 20 July 2011

Mi-Pilo




Mi-Pilo may be available in the countries listed below.


Ingredient matches for Mi-Pilo



Pilocarpine

Pilocarpine hydrochloride (a derivative of Pilocarpine) is reported as an ingredient of Mi-Pilo in the following countries:


  • Israel

International Drug Name Search

Biocil




Biocil may be available in the countries listed below.


Ingredient matches for Biocil



Povidone Iodine

Povidone-Iodine is reported as an ingredient of Biocil in the following countries:


  • New Zealand

International Drug Name Search